Pharma Mar, S.A.

Pharma Mar, S.A.

PHMMF

$70.70

Updated: 05/11/2026, 00:37:41

Market Cap
$1.23B
Sector
Healthcare
Industry
Biotechnology
Country
ES

No historical data available

Company Profile

Pharma Mar, S.A. is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of bioactive compounds derived from marine organisms, primarily targeting oncology applications. Its products and research initiatives reach across key markets including Spain, Italy, Germany, Ireland, the broader European Union, the United States, and other international territories. The company's operations are structured across three distinct segments: Oncology, Diagnostics, and RNA Interference. Within its oncology portfolio, Pharma Mar markets Yondelis®, prescribed for soft tissue sarcomas and ovarian cancer, alongside Aplidin® for multiple myeloma, and Zepzelca®, which addresses small cell lung cancer. Additionally, the company has PM14, currently undergoing Phase II clinical trials for the treatment of various solid tumors. Beyond oncology, the Diagnostics segment is involved in the development and sale of diagnostic kits. Furthermore, through its RNA Interference division, Pharma Mar is advancing therapeutics designed to modulate or silence gene expression for therapeutic benefit. Established in 1986, the company maintains its headquarters in Madrid, Spain.

USD
OTC
CEO: Jose Maria Fernandez Sousa-Faro
Employees: 505
https://www.pharmamar.com
Asset Summaries
Latest generated summaries for PHMMF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for PHMMF.
Share price
$70.70
Market cap
$1.23B
Exchange
OTC
Currency
USD
CEO
Jose Maria Fernandez Sousa-Faro
Employees
505
IPO date
23/02/2016
Beta
0.699
Last dividend
$0.00
Day range
$70.70 – $70.70
52-week range
$70.70 – $106.48
1-day performance
-8.29%
1-year performance
0.00%
Current drawdown (1Y)
-33.60%
CIK
N/A
CUSIP
N/A
ISIN
ES0169501022
Created
07/12/2025, 05:44:54
Last update
05/11/2026, 00:37:41

Track Pharma Mar, S.A. with an AI analyst

See which prediction-market events move PHMMF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.